SAB Biotherapeutics Names David Zaccardelli as Board Chair and Rita Jain as Director
Reuters
Jan 07
<a href="https://laohu8.com/S/SABS">SAB Biotherapeutics</a> Names David Zaccardelli as Board Chair and Rita Jain as Director
SAB Biotherapeutics Inc. has appointed David Zaccardelli, Pharm.D., as Chair of the Board of Directors and Rita Jain, M.D., as an independent director. These appointments are effective immediately as the company advances its lead therapy, SAB-142, for type 1 diabetes and other autoimmune diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621038) on January 07, 2026, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.